

cancer drugs (e.g. paclitaxel). Our aim is to develop different experimental glioma models in mice with intact and locally disrupted BBB to study the efficacy of better treatment modalities for gliomas.

Methods: Tumor cell lines of different origin were implanted intracranially in nude mice. To allow non-invasive monitoring of tumor growth in vivo, cell lines were tagged with the firefly luciferase-gene. Tumor growth was monitored using the IVIS camera (Xenogen Inc.). Vascular leakage in the tumor (a measure for BBB properties) was detected using 7T contrast enhanced MRI with gadolinium-DTPA. Mice implanted with Mel57 cells were treated with i.v. paclitaxel at 9, 11 and 13 days after tumor cell implantation.

Results: The implantation of the different cell lines resulted in xenograft mouse models for glioma, displaying the infiltrative, invasive and expansive growth characteristics of a glioma with or without intact BBB properties (Table). Tumor growth could already be visualized 6 days after implantation of the tumor cells. The relationship between tumor mass and bioluminescence was validated using standard histological techniques. So far, we have tested the efficacy of paclitaxel against intracranial Mel57 cells and did not observe a significant decrease of tumor growth.

Cell-line	Species	Origin	Growth pattern	BBB
U-87	Human	Glioblastoma	Expansive, angiogenic	Not intact
U-118	Human	Glioblastoma	No growth	—
K1735	Murine	Melanoma	Infiltrative, co-optive	Intact
Mel57	Human	Melanoma	Invasive, co-optive	Intact
Mel57VEGF165	Human	Melanoma	Expansive, angiogenic	Not intact
SMT	Human	Melanoma	Expansive, some invasion	To be determined
MDA MB 435	Human	Breast	Expansive, angiogenic	To be determined

Conclusions: We have successfully developed several glioma models in mice. In vivo imaging by luciferase allows convenient follow-up of tumor growth for intervention studies. Paclitaxel is not effective against implanted Mel57 cells, a tumor that is protected by the BBB, and we expect that the BBB plays an important role in this inefficacy of paclitaxel. To further study the role of the BBB in the protection of brain tumors, we are currently extending our experiments in the other tumor models. Moreover, since paclitaxel is a substrate of the drug transporter P-glycoprotein (Pgp), we are also studying the effect of Pgp in the BBB using Pgp deficient mice.

Ovarian cancer

36

ORAL

Paclitaxel/Carboplatin (TC) vs Paclitaxel/Carboplatin sequentially followed by Topotecan (TC-Top) in first-line treatment of ovarian cancer FIGO stages IIB - IV Interim results of a gynaecologic cancer intergroup phase III trial of the AGO ovarian cancer study group and Gineco

E. Pujade-Lauraine¹, J. Pfisterer², A. Lortholary¹, R. Kimmig², B. Weber¹, A. du Bois², H. Bourgeois¹, U. Wagner², W. Meier², S. Costa². ¹GINECO, France; ²AGO Ovarian Cancer Group, Germany

Between 12/1999 and 03/2002 1308 patients were randomized to receive 6 cycles of Paclitaxel (175 mg/m² 3h iv) and Carboplatin (AUC 5, Calvert formula) followed by surveillance (TC) or by 4 cycles of Topotecan (1.25 mg/m² iv d1-5) (TC-Top) on a 3 weekly schedule. The primary objective was to test for superiority of TC-Top in terms of overall survival. Currently 929 end of therapy reports have been issued, 87% completed 6 or more therapy courses. Treatment and toxicity data are complete in 98%. TC-Top produced a markedly higher myelotoxicity resulting in treatment delays in 21% of the Topotecan courses. Grade 3/4 anemia occurred in 17% of all Topotecan courses, thrombocytopenia in 30%, neutropenia in 77%. There was no clinical relevance in terms of febrile neutropenia (2%) or infections (3%). The mean Topotecan dose/course for all 4 courses was 1.22 mg/m². In non-hematologic toxicity no significant differences between TC and TC-Top could be observed. TC-Top is a safe first line regimen in advanced ovarian cancer. In both study arms TC and TC-Top the mean and median doses were given as scheduled, as were the median and mean intervals between therapy courses. Follow up will be updated in summer 2003. First efficacy data (response, progression free survival and survival) will also be available in summer 2003.

37

ORAL

Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer (AOC): long-term efficacy results

G. Aravantinos, G. Fountzilas, P. Kosmidis, Ma. Dimopoulos, Gp. Stathopoulos, N. Pavlidis, D. Bafaloukos, S. Rigatos, S. Karpathios, Dv. Skarlos. *Hellenic Cooperative Oncology Group, Athens, Greece*

Introduction: Carboplatin combined with paclitaxel are considered treatment of choice as initial chemotherapy for advanced ovarian cancer. We compared this combination with a regimen combining alternating carboplatin and cisplatin plus paclitaxel. The two platinum derivatives have been previously combined as they are considered not totally cross-resistant and as they share no overlapping toxicities, in order to increase the total platinum dose intensity and consequentially the disease outcome.

Material and methods: Patients with AOC after the initial cytoreductive surgery were stratified according to the FIGO stage and the presence of residual disease and were randomized to either combination of 6 courses of chemotherapy with paclitaxel at 175mg/m² as 3h infusion plus Carboplatin 7AUC (Arm A) or paclitaxel at the same dose plus Carboplatin 7AUC for cycles 1,3,5 and Cisplatin at 75mg/m² for cycles 2,4,6 (Arm B). Primary endpoints were disease free survival (DFS) and overall survival (OS).

Results: 247 patients are analyzed 121 in arm A, 126 in Arm B. 73% of the patients had stage III and 18% stage IV disease. Chemotherapy was generally well tolerated and treatment delays or dose reductions were not necessary. Toxicity and short-term efficacy results have been reported previously [Seminars in Oncology, 1997, 24 (5), (suppl 15), 15-21. Proc Am Soc Clin Oncol 1999;18:367a (1416)]. With a median follow up of 61 months statistically significant differences were not found, both in terms of time to progression (38 vs 39 months, p=0.95) and overall survival (40.6 vs 38.6 months, p=0.79). There is not also difference in 5-year survival rate (35% vs 39%) or 5-year disease free survival rate (23% vs 28%).

Conclusion: Both regimens are well tolerated and effective as first line chemotherapy of advanced ovarian cancer with very good long term outcome. Alternating cisplatin with carboplatin does not improve the results as compared with the standard carboplatin/paclitaxel combination.

38

ORAL

Influence of amifostine on neuroprotection in 1st-line treatment of advanced ovarian cancer with carboplatin/taxane-based chemotherapy - a double-blind, placebo-controlled, randomized phase II-study from the AGO Ovarian Cancer Study Group

P. Wimberger¹, R. Kimmig¹, F. Hilpert², A. Stähle³, A. Burges⁴, O. Tomé⁵, D. Rossner⁶, K. Späthel⁷, V. Heilmann⁸, A. du Bois^{3,9}. ¹University of Essen, Obstetrics and Gynecology, Essen, Germany; ²University of Kiel, Obstetrics and Gynecology, Kiel, Germany; ³St. Vincentius-Krankenhäuser Karlsruhe, Obstetrics and Gynecology, Karlsruhe, Germany; ⁴University of Munich- Großhadern, Obstetrics and Gynecology, Munich, Germany; ⁵University of Tübingen, Obstetrics and Gynecology, Tübingen, Germany; ⁶Med. Hochschule Hannover, Oststadtkrankenhaus, Obstetrics and Gynecology, Hannover, Germany; ⁷Klinikum rechts der Isar, Munich, Obstetrics and Gynecology, Munich, Germany; ⁸University of Ulm, Obstetrics and Gynecology, Ulm, Germany

Neurotoxicity (NT) is one of the most important problem of platinum/taxane-based therapy of ovarian cancer (OC) with high impact on quality of life (QoL). We therefore performed a double-blind randomized and placebo-controlled multi-center trial to evaluate the influence of the cytoprotectant amifostine (AM) on NT in 1st-line therapy of OC with paclitaxel (T)/carboplatin (C) +/- epirubicin (E). 71 patients were stratified for 1st-line chemotherapy with T 175 mg/m² and C AUC5 with or without E 60 mg/m² (q21x6) and randomized for premedication with AM 740 mg/m² i.v. (n = 37) or a placebo i.v. (n = 34) (30 min. prior to chemotherapy). NT was evaluated by an objective assessment with measurement of Patella (TRA) and Achilles tendon reflex activity, vibration perception threshold (VPT) and 2-point discrimination (2-PD) and additionally by a questionnaire concerning specific neurotoxic symptoms and motoric abilities. Supplementary, toxicities were assessed according to the NCI-CTC and QoL. The majority of NT criterions showed a significant impairment during therapy in both treatment arms. A significant protective effect of AM was observed for the objective assessment with TRA, 2-PD, and VPT with regard to intensity and time dependence of pathological findings. AM significantly improved a number of QoL-subscores, but failed to better the global health status score significantly (p=0.3469). Toxicities according to NCI-CTC showed improved sensory neuropathy (0,0046) in the AM group but on the other hand a significant higher

percentage for nausea ($p = 0.0005$) and vomiting ($p = 0.0083$). No significant differences were observed for specific sensory and motoric neurotoxic symptoms, except for a better skilfulness in the AM group ($p = 0.0404$). In conclusion, AM improved sensory neuropathy according to NCI-CTC and results from objective neurological assessment, but there were almost no differences in self-estimated specific sensory or motoric symptoms. Disadvantages with regard to other toxicities and inconsistent results for QoL demand further evaluation of neuroprotection with AM in the treatment of OC. At this moment the presented results do not justify a standardized additional application of AM to platinum/taxane-based chemotherapy.

39

ORAL

Topotecan versus treosulfan in recurrent ovarian cancer after initial chemotherapy with platinum and paclitaxel. a prospective randomised phase III study of the AGO ovarian cancer study group.

S. Loibl¹, W. Meier², A. du Bois³, W. Kuhn⁴, J. Pfisterer⁵, R. Kimmig⁶, S. Olbricht⁷, B. Richter⁸. ¹University Hospital Frankfurt, Department of Obstetrics and Gynaecology, Frankfurt, Germany; ²Evangelisches Krankenhaus, Department of Obstetrics and Gynecology, Düsseldorf, Germany; ³Horst-Schmidt Klinik, Department of Gynecology and Oncology, Wiesbaden, Germany; ⁴University Hospital, Department of Obstetrics and Gynaecology, Bonn, Germany; ⁵University Hospital Kiel, Department of Obstetrics and Gynecology, Kiel, Germany; ⁶University Hospital Essen, Department of Obstetrics and Gynaecology, Essen, Germany; ⁷University Hospital Magdeburg, Department of Obstetrics and Gynaecology, Magdeburg, Germany; ⁸Krankenhaus Radebeul, Department of Obstetrics and Gynaecology, Radebeul, Germany

Background: After initial radical debulking surgery followed by combination chemotherapy most ovarian cancer patients will eventually relapse and will be in need of further treatment. Standard chemotherapy for recurrent disease after first line treatment with carboplatin and paclitaxel is not yet defined. Therefore, this multi-centre, prospective randomised trial, was conducted to compare the topoisomerase I inhibitor topotecan with the alkylating agent treosulfan in patients with relapsed ovarian cancer.

Material and Methods: The study was undertaken to define the progression-free survival time and the response rate. Patients were stratified according to treatment free interval: relapse between 0-6 or 6-12 months after end of primary treatment (2nd line) or relapse after re-induction chemotherapy with a platinum-containing regimen (3rd line). The therapy consisted of 1.5 or 1.25 (3rd line) mg/m² topotecan, d1-5 every three weeks or 7.0 or 5.0 (3rd line) g/m² treosulfan. In patients with SD or PR, treatment was continued until disease progression or intolerable toxicity occurred.

Results: 357 patients were recruited (topotecan 178, treosulfan 179), 8 patients were withdrawn after randomisation. Patient characteristics were equally distributed between the two groups. Significantly more patients progressed after treosulfan treatment compared to topotecan treatment (62.5% vs. 28.4%, respectively). Response data were validated by external radiological review. Haematologic toxicity grade 3/4 was more frequently observed during topotecan therapy: neutropenia in 46.8% vs. 5.4%, thrombocytopenia in 7.4% vs 1.5% and anaemia in 4.3% vs. 1.0% of the courses compared to treosulfan. Grade 3/4 infection was 2.9% and 1.1% for topotecan and treosulfan, respectively, demonstrating no significant clinical consequences caused by topotecan haematologic toxicity. Non-haematologic toxicities were mild and apart from alopecia, comparable in both treatment groups. The progression-free survival was 5.4 months in the topotecan group and 3.0 months in patients treated with treosulfan ($p < 0.0001$, all patients). The analysis of the subgroups is still ongoing.

Conclusion: This clearly stratified randomised study in exactly defined recurrent ovarian cancer patients after carboplatin/paclitaxel initial therapy demonstrates that, both regimens are well tolerated without clinically relevant side effects. It can therefore be concluded that, topotecan may be defined as the new standard in early recurrent ovarian cancer because of the improved progression free survival and remission rate.

40

ORAL

Prognostic significance of P53, EGFR and Her-2 expression in borderline and epithelial ovarian cancer.

J. Stab Nielsen¹, E. Jakobsen², B. Hoelund³, K. Bertelsen⁴, A. Jakobsen⁵. ¹University of Southern Denmark, Department of Oncology, Vejle Hospital, Vejle, Denmark; ²Vejle Hospital, Department of Oncology, Vejle, Denmark; ³Odense University Hospital, Institute of Pathology, Odense, Denmark; ⁴Odense University Hospital, Department of Oncology, Odense, Denmark; ⁵Vejle Hospital, Department of Oncology, Vejle, Denmark

The study was approved by the Danish Ovarian Cancer Study Group (DACOVA), Odense University Hospital.

Background: Epithelial ovarian cancer (EOC) continues to represent a challenge in cancer treatment despite advances especially in the application of new cytostatic drugs. Several aspects are not yet elucidated and important prognostic factors still need to be defined.

Several molecular-biological factors have been investigated in order to reveal new prognostic factors. Prior studies have assessed the prognostic relevance of P53-protein, EGFR and Her-2 receptors using immuno-histochemical methods. So far no previous study has evaluated the prognostic significance of all three factors including a large number of patients with a long follow-up period. The objective of the present study was to evaluate the prognostic significance of p53, EGFR and Her-2 in relation to currently known prognostic factors.

Material and methods: The study was based on two cohorts diagnosed from 1981-86 and 1991-94. 1073 patients were retrieved from the registry of DACOVA. Archival paraffin-embedded tissue blocks from the primary surgery were retrieved from the regional departments of pathology. One senior gynaecological pathologist who had no knowledge of clinical data and outcome performed histo-pathological revision. Only patients with confirmed borderline or frank epithelial ovarian cancer at revision were included. Representative samples of tissue were chosen from each patient and three tissue-slides were stained immuno-histochemically to assess p53, EGFR and Her-2.

The slides were evaluated semi-quantitatively in a light-microscope by one of the investigators who had no knowledge of clinical data and outcome. One hundred slides from each factor were selected by random in order to evaluate inter and intra-observer variation.

Results: From the initial 1073 patients 202 were excluded at time of revision. Another 3 patients were excluded just prior to statistical analysis due to missing data on revision, resulting in subset of 868 patients. Preliminary results including univariate analyses show a statistically significant association between overexpression of p53 ($p < 0.001$) and Her-2 ($p = 0.027$) and decreased survival. EGFR-overexpression was not significantly associated with a decrease in survival ($p = 0.15$). The classical prognostic factors age, stage, histology and grade were all significantly associated with survival. Multivariate analyses are in preparation and will be presented at the conference.

Reproducibility for all receptors was acceptable with kappa-values between 0.57-0.88.

Conclusions: Preliminary results indicate that p53 and Her-2 may be defined as prognostic factors in epithelial ovarian cancer; EGFR, however, did not prove to be a prognostic factor.

41

ORAL

HER2- expression in advanced ovarian cancer: A prognostic and predictive marker? An Study of the AGO Ovarian Study Group

H.J. Lück¹, F. Kommoss², E. Riener³, N. Arnold³, H.P. Adams⁴, F. Hilpert⁵, A. Du Bois⁶, J. Pfisterer³. ¹Med. Univ. Hannover, Gyn. Oncology, Hannover, Germany; ²Univ. Mannheim, Dept. of Pathology, Mannheim, Germany; ³Univ. Schleswig-Holstein, Dept. Gyn. and Obst., Kiel, Germany; ⁴AGO Study Group Ovarian Cancer, Wiesbaden, Germany; ⁵Univ. Schleswig-Holstein, Dept. Gyn., Kiel, Germany; ⁶HSK Wiesbaden, Dept. Gyn. and Gyn. Oncol., Wiesbaden, Germany

In contrast to breast cancer the role of HER2 overexpression in ovarian cancer is under discussion. Up to now only small studies with contradictory results are published. The aim of this study was to analyse the role of HER2 overexpression in a uniform treated population of patients with advanced ovarian cancer, as a prognostic and/or predictive factor.

Materials and methods: The paraffin blocks of 361 patients from the AGO Ovar-3 trial were retrospectively analysed for HER2 expression (immunohistochemical DAKO antibody, and with FISH). The HER2 data were correlated for clinical factors.